JS004 is named as a drug or biological intervention in 4 clinical trials in our China trial register, 3 of which are recruiting. Lead sponsors include Shanghai Junshi Bioscience Co., Ltd. (2) and Fudan University (2). Registered phases: Phase 2, Phase 3 and Phase 1/2. Conditions studied include Hodgkin Lymphoma; Pancreatic Cancer; Advanced NSCLC.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06170489 | A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) (ClinicalTrials.gov ↗) Hodgkin Lymphoma |
Phase 3 | Recruiting |
| NCT06690697 | Combination of Toripalimab and JS004 Therapy for ccRCC (ClinicalTrials.gov ↗) Clear Cell Renal Cell Carcinoma |
Phase 2 | Recruiting |
| NCT06924606 | Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy (ClinicalTrials.gov ↗) Advanced NSCLC |
Phase 2 | Recruiting |
| NCT06370754 | Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (ClinicalTrials.gov ↗) Pancreatic Cancer |
Phase 1/2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Hodgkin Lymphoma | 1 |
| Pancreatic Cancer | 1 |
| Advanced NSCLC | 1 |
| Clear Cell Renal Cell Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Shanghai Junshi Bioscience Co., Ltd. | 2 |
| Fudan University | 2 |
| Register | JS004 trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how JS004 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists JS004 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.